Clinical Trial Update: Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals [Phase 4]

View source ↗

Summary

Phase 4 trial update examining changes in weight, body composition and cardiac risk after stopping abacavir in HIV-infected individuals. The study status is com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• HIV Infection
• Hiv-associated Cardiomyopathy
• Hiv-associated Lipodystrophy

Drugs mentioned

• Ziagen (Abacavir)

Snippet

Sponsor: Thomas Benfield | Conditions: Hiv, HIV Infections | Phase 4 | Status: COMPLETED